Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:16 AM
Ignite Modification Date:
2025-12-25 @ 4:16 AM
NCT ID:
NCT02129920
Eligibility Criteria:
Inclusion Criteria:
* Clinical diagnosis of acute ischemic stroke or transient ischemic attack (TIA)
* Having non-valvular atrial fibrillation
* Visiting the clinic/hospital within 48 hours of the onset of acute ischemic stroke or TIA
* Identification of an infarct in the middle cerebral artery (MCA) territory (symptoms ascribable to ischemia in the MCA territory in TIA patients)
* Initiation of treatment with rivaroxaban within 30 days of the onset of acute ischemic stroke or TIA
* Written informed consent by patients
Exclusion Criteria:
* hypersensitivity to rivaroxaban 2) Active bleeding (clinically significant hemorrhage) including gastrointestinal hemorrhage
* liver disease complicated with coagulation disorder
* liver disorder corresponding to Child-Pugh Class B or C
* renal failure (creatinine clearance: \<15 mL/minute)
* poorly controlled hypertension (higher than 180/100)
* Woman who are or are likely to be pregnant
* Ongoing treatment with HIV protease inhibitors including ritonavir, atazanavir and indinavir
* Ongoing treatment with itraconazole, voriconazole and ketoconazole
* Active bacterial endocarditis
* Patients considered by the investigator to be unsuitable for participating in this study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT02129920
Study Brief:
Protocol Section:
NCT02129920